NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

HUTCHMED (China) Limited (HCM) Stock Analysis

HUTCHMED (China) Limited (HCM) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

HCM

$14.37

−$0.37 (−2.51%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HCM with… →

HCM Key Statistics

As of Oct 21, 2026
Trading
Open
$14.70
Previous Close
$14.74
Day's Range
14.37–14.71
52-Week Range
9.77–16.33
Volume
72.37K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.36
Valuation
Market Cap
$2.50B
P/E Ratio
143.70
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
55.44
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.55
EPS (ttm)Profit attributable to each share over the last twelve months.
0.10
Financials (FY)
Revenue (FY)
$548.51M−12.96%
Net Income (FY)
$456.91M+1,111.03%
Profit marginThe share of revenue left as profit after all costs and taxes.
3.26%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
173.81M
1-Year Return
−5.46%
Dividend and dates
Avg Volume
68.12K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HCM closed at $14.37, −5.46% over 1 year.

HUTCHMED (China) Limited (HCM) has a market capitalization of $2.50B.

In fiscal 2025, HCM reported revenue of $548.51M.

HCM Stock Return by Calendar Year

HUTCHMED (China) Limited (HCM) 10-year return: what $10,000 became

1 year
$10,000 $9,454
−5.46%
5 years
$10,000 $4,467
−55.33%
10 years
$10,000 $12,314
+23.14%

If you had invested $10,000 in HUTCHMED (China) Limited (HCM) 10 years ago, at the close on October 21, 2016, it would have been worth $12,314 at the close on October 21, 2026: +23.14% in total, +2.10% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+7.80%
2025−7.49%
2024−20.43%
2023+22.53%
2022−57.87%
2021+9.56%
2020+27.72%
2019+8.58%
2018−41.43%
2017+190.49%
2016 (partial year)+4.22%

As of October 21, 2026.

HCM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$548.51M$456.91M83.3%
2024$630.20M$37.73M6.0%
2023$838.00M$100.78M12.0%
2022$426.41M−$360.84M−84.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$548.51M$212.16M−$35.70M$456.91M83.3%
2024$630.20M$281.32M−$40.61M$37.73M6.0%
2023$838.00M$453.55M$21.51M$100.78M12.0%
2022$426.41M$115.31M−$406.26M−$360.84M−84.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HCM Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricHCMDrug Manufacturers - Specialty & Generic medianvs median
P/E143.7020.317.1x the median
P/S ratio4.552.10117% above
Profit margin3.26%−8.14%11.4 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

HUTCHMED (China) Limited (HCM) carries a market capitalisation of $2.50B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 1,790.

The 52-week range on file runs from $9.77 to $16.33. The most recent close on file for HCM is $14.37, dated October 21, 2026. That is −$0.37 (−2.51%) against the previous close. The latest close sits 47.08% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $548.51M. Against the prior fiscal year total of $630.20M, that is a change of −12.96%. The same year closed with net income of $456.91M. That is +1,111.03% against the prior fiscal year. Profit margin runs at 3.26%. That is 11.4 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are 0.1.

Across the 4 fiscal years on file, revenue moves from $426.41M in 2022 to $548.51M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 143.7 times earnings. That is 7.1 times the Drug Manufacturers - Specialty & Generic median of 20.31. On forward earnings the ratio is 55.44. The price-to-sales ratio is 4.55. On price-to-sales that is 116.6% above the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The reported beta is 0.36. Annualized volatility over the trailing 10 years is 59.91%. Over the trailing twelve months the total return is −5.46%. Across 10 years the annualized return works out at +2.10%.

Growth & Income

No dividend is on file for HCM.

The strongest complete calendar year on file is 2017 at +190.49%; the weakest is 2022 at −57.87%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the total return is +7.80%.

Peer Comparison

HUTCHMED (China) Limited (HCM) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
HUTCHMED (China) Limited HCM $2.50B 143.7
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. HUTCHMED (China) Limited trades at a P/E of 143.7.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About HUTCHMED (China) Limited

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Visit website →